검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | pentostatin |
Overview Company | Incyte Corporation |
Overview Modality | CGT |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targets the cell surface antigen |
MoA Biomarker | biomarker of disease activity and a potential therapeutic target |
PK/PD Half-life | 5.7 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.. Hairy cell leukemia (HCL) is a rare, indolent lymphoproliferative disorder that is highly responsive to purine analog therapy. While agents such as cladribine and pentostatin remain standard front-line therapies, their long-term toxicities-particularly myelosuppression and immune dysfunction-hav… |
Toxicology CRS | Reported |
Clinical OS | 2 |
Clinical Result source | ClinicalTrials.gov NCT00402714 |
Clinical Data Tier / Score | A · 16 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | pentostatin |
Overview Company | Incyte Corporation |
Overview Modality | CGT |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targets the cell surface antigen |
MoA Biomarker | biomarker of disease activity and a potential therapeutic target |
PK/PD Half-life | 5.7 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.. Hairy cell leukemia (HCL) is a rare, indolent lymphoproliferative disorder that is highly responsive to purine analog therapy. While agents such as cladribine and pentostatin remain standard front-line therapies, their long-term toxicities-particularly myelosuppression and immune dysfunction-hav… |
Toxicology CRS | Reported |
Clinical OS | 2 |
Clinical Result source | ClinicalTrials.gov NCT00402714 |
Clinical Data Tier / Score | A · 16 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교